Touami Sofia reported LYCA

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002159567-26-000005

Machine-readable

Structured copy

Timestamps

Event (reported)

Aug 11, 2026

Published

Oct 26, 2026

Ingested by INSIDER

Nov 5, 02:09 UTC

Last re-read

Nov 5, 02:09 UTC

Extracted facts

Filer

Touami Sofia

Role

Chief Business Officer

Transaction

Grant or awardAs filed: “A”

Asset

Lycia Therapeutics, Inc. — Stock Option (Right to Buy)

Ticker

LYCA

Shares

68.8K

Price per share

$0

Execution date (reported)

Aug 11, 2026

Owned after transaction

68.8K shares

Days from execution to publication

76

What this establishes

Touami Sofia filed this Form 4 reporting a grant or award of LYCA on Aug 11, 2026. It became public on Oct 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Chief Business Officer

Touami Sofiacik:0002159567

Issuer

Lycia Therapeutics, Inc.cik:0001806540

Revision history · 0

No field has changed since this record was first ingested.